Company Management, Scientific and Advisory Boards

Breast Cancer publications

Hachemi, M., Couturier, O., Vervueren, L., Fosse, P., Lacœuille, F., Urban, T., & Hureaux, J. (2014). [18F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients. PLoS ONE, 9(2), e87629. https://doi.org/10.1371/journal.pone.0087629
Eliat, P.-A., Dedieu, V., Bertino, C., Bouté, V., Lacroix, J., Constans, J.-M., … Vincensini, D. (2004). Magnetic resonance imaging contrast-enhanced relaxometry of breast tumors: an MRI multicenter investigation concerning 100 patients. Magnetic Resonance Imaging, 22(4), 475–481. https://doi.org/10.1016/j.mri.2004.01.024
Maxwell, F., de Margerie Mellon, C., Bricout, M., Cauderlier, E., Chapelier, M., Albiter, M., … de Bazelaire, C. (2015). Diagnostic strategy for the assessment of axillary lymph node status in breast cancer. Diagnostic and Interventional Imaging, 96(10), 1089–1101. https://doi.org/10.1016/j.diii.2015.07.007
de Bazelaire, C., Pluvinage, A., Chapelier, M., Hamy, A. S., Albiter, M., Farges, C., … Frija, J. (2010). [Diffusion-weighted MR imaging of the breast]. Journal De Radiologie, 91(3 Pt 2), 394–404; quiz 405–407. https://doi.org/10.1016/s0221-0363(10)70055-x
Fosse, P., Girault, S., Capitain, O., Valo, I., Bouchet, F., Vervueren, L., … Morel, O. (2012). Apport de la TEP-FDG dans le staging initial des cancers du sein localement avancés traités par chimiothérapie néo-adjuvante. Médecine Nucléaire, 36(2), 69–76. https://doi.org/10.1016/j.mednuc.2011.11.011
Rousseau, C., Devillers, A., Campone, M., Campion, L., Ferrer, L., Sagan, C., … Kraeber-Bodéré, F. (2011). FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 38(6), 1029–1036. https://doi.org/10.1007/s00259-011-1735-y
Cochet, A., Quilichini, G., Dygai-Cochet, I., Touzery, C., Toubeau, M., Berriolo-Riedinger, A., … Brunotte, F. (2011). Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Research and Treatment, 130(3), 845–854. https://doi.org/10.1007/s10549-011-1714-9
Lehmann-Che, J., Amira-Bouhidel, F., Turpin, E., Antoine, M., Soliman, H., Legres, L., … Bertheau, P. (2011). Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. British Journal of Cancer, 104(11), 1739–1746. https://doi.org/10.1038/bjc.2011.135
de Bazelaire, C., Calmon, R., Thomassin, I., Brunon, C., Hamy, A.-S., Fournier, L., … Cuénod, C.-A. (2011). Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study. BMC Cancer, 11(1), 361. https://doi.org/10.1186/1471-2407-11-361
Humbert, O., Berriolo-Riedinger, A., Riedinger, J. M., Coudert, B., Arnould, L., Cochet, A., … Brunotte, F. (2012). Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Annals of Oncology, 23(10), 2572–2577. https://doi.org/10.1093/annonc/mds071
Thomassin-Naggara, I., De Bazelaire, C., Chopier, J., Bazot, M., Marsault, C., & Trop, I. (2013). Diffusion-weighted MR imaging of the breast: Advantages and pitfalls. European Journal of Radiology, 82(3), 435–443. https://doi.org/10.1016/j.ejrad.2012.03.002
Hamy, A.-S., Giacchetti, S., Albiter, M., de Bazelaire, C., Cuvier, C., Perret, F., … Espie, M. (2012). BI-RADS categorisation of 2708 consecutive nonpalpable breast lesions in patients referred to a dedicated breast care unit. European Radiology, 22(1), 9–17. https://doi.org/10.1007/s00330-011-2201-8
Groheux, D., Hindie, E., Delord, M., Giacchetti, S., Hamy, A. -s., de Bazelaire, C., … Espie, M. (2012). Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. JNCI Journal of the National Cancer Institute, 104(24), 1879–1887. https://doi.org/10.1093/jnci/djs451
de Bazelaire, C., Groheux, D., Chapellier, M., Sabatier, F., Scémama, A., Pluvinage, A., … de Kerviler, E. (2012). Breast inflammation: Indications for MRI and PET-CT. Diagnostic and Interventional Imaging, 93(2), 104–115. https://doi.org/10.1016/j.diii.2011.12.004
Thureau, S., Chaumet-Riffaud, P., Modzelewski, R., Fernandez, P., Tessonnier, L., Vervueren, L., … Vera, P. (2013). Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3’-Deoxy-3’-18F-Fluorothymidine PET Images in Lung Cancer. Journal of Nuclear Medicine, 54(9), 1543–1550. https://doi.org/10.2967/jnumed.112.118083
Richard, R., Thomassin, I., Chapellier, M., Scemama, A., de Cremoux, P., Varna, M., … de Bazelaire, C. (2013). Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. European Radiology, 23(9), 2420–2431. https://doi.org/10.1007/s00330-013-2850-x
Lehmann-Che, J., Hamy, A.-S., Porcher, R., Barritault, M., Bouhidel, F., Habuellelah, H., … Bertheau, P. (2013). Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Research, 15(3), R37. https://doi.org/10.1186/bcr3421
de Bazelaire, C., Scémama, A., Coffin, A., Cohen, S., Chapellier, M., Sabatier, F., … de Kerviler, E. (2013). Perfusion studies in senology. Diagnostic and Interventional Imaging, 94(12), 1279–1290. https://doi.org/10.1016/j.diii.2013.06.011
Bousquet, G., Varna, M., Ferreira, I., Wang, L., Mongiat-Artus, P., Leboeuf, C., … Janin, A. (2013). Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis. Cancer Chemotherapy and Pharmacology, 72(6), 1183–1193. https://doi.org/10.1007/s00280-013-2300-0
Frings, V., Yaqub, M., Hoyng, L. L., Golla, S. S. V., Windhorst, A. D., Schuit, R. C., … for the QuIC-ConCePT Consortium. (2014). Assessment of Simplified Methods to Measure 18F-FLT Uptake Changes in EGFR-Mutated Non-Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment. Journal of Nuclear Medicine, 55(9), 1417–1423. https://doi.org/10.2967/jnumed.114.140913
Thomassin-Naggara, I., Perrot, N., Dechoux, S., Ribeiro, C., Chopier, J., & de Bazelaire, C. (2015). Added value of one-view breast tomosynthesis combined with digital mammography according to reader experience. European Journal of Radiology, 84(2), 235–241. https://doi.org/10.1016/j.ejrad.2014.10.022
Bousquet, G., Feugeas, J.-P., Ferreira, I., Vercellino, L., Jourdan, N., Bertheau, P., … Janin, A. (2014). Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma. Breast Cancer Research, 16(1), 401. https://doi.org/10.1186/bcr3615
Bousquet, G., Darrouzain, F., de Bazelaire, C., Ternant, D., Barranger, E., Winterman, S., … Janin, A. (2016). Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. Journal of Clinical Oncology, 34(16), e151–e155. https://doi.org/10.1200/JCO.2012.44.8894
de Margerie-Mellon, C., Kaci, R., Laredo, J.-D., & Bousson, V. (2015). Multiple small sclerotic bone lesions revealing invasive lobular breast carcinoma. Joint Bone Spine, 82(2), 129–130. https://doi.org/10.1016/j.jbspin.2014.08.002
Le Guennec, L., Bertrand, A., Laurent, C., Roze, H., Chastre, J., Combes, A., & Luyt, C.-E. (2015). Diffuse Cerebral Microbleeds after Extracorporeal Membrane Oxygenation Support. American Journal of Respiratory and Critical Care Medicine, 191(5), 594–596. https://doi.org/10.1164/rccm.201411-2118LE
Vera, P., Thureau, S., Chaumet-Riffaud, P., Modzelewski, R., Bohn, P., Vermandel, M., … Dubray, B. (2017). Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18 F-Misonidazole PET/CT in Patients with Non–Small Cell Lung Carcinoma (RTEP5 Study). Journal of Nuclear Medicine, 58(7), 1045–1053. https://doi.org/10.2967/jnumed.116.188367